Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Drug resistance continues to be a major problem associated with cancer treatment. One of the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In particular, considerable efforts have been made to treat KRAS-induced cancers by directly and indirectly controlling the ac...
Guardado en:
Autores principales: | Soonsil Hyun, Dongyun Shin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/69812bda3185416abd49d119a6d7fd35 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
Mutación del gen KRAS en el cáncer de colon y recto
por: Roa,Iván, et al.
Publicado: (2013) -
Prevalencia y características de mutaciones somáticas del gen KRAS en pacientes chilenos con cáncer colorrectal
por: Hurtado,Claudia, et al.
Publicado: (2014) -
CRISPR and KRAS: a match yet to be made
por: Guzide Bender, et al.
Publicado: (2021) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu X, et al.
Publicado: (2019)